Related Experiment Video

Updated: Jun 1, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

[Antibiotic therapy in community acquired pneumonia in children]

Marek Kulus1

  • 1Warszawski Uniwersytet Medyczny, Klinika Pneumonologii i Alergologii Wieku Dzieciecego. marek.kulus@wum.edu.pl

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|June 17, 2011
PubMed

Insights

Pneumonia remains a primary reason for antibiotic treatment in children, even as incidence declines. This paper reviews current data on causes, diagnosis, and treatment guidelines for childhood pneumonia.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Epidemiology

Context:

  • Pneumonia is a leading cause of antibiotic initiation in pediatric patients.
  • Recent epidemiological data suggest a potential decrease in pneumonia incidence.
  • Current treatment guidelines and diagnostic approaches require ongoing evaluation.

Purpose:

  • To discuss current data on the etiology, diagnostics, and guidelines for childhood pneumonia.
  • To describe empirical antibiotic therapy for pediatric pneumonia across different age groups.
  • To highlight future research directions for resolving current guideline controversies.

Summary:

  • This review examines the etiology and diagnostics of childhood pneumonia, a significant driver of antibiotic use.
  • It details current empirical antibiotic therapy strategies based on age groups.
  • The paper addresses evolving epidemiological data and controversies in existing treatment guidelines.

Impact:

  • Provides an updated overview of childhood pneumonia management.
  • Informs clinicians on current best practices for empirical antibiotic therapy.
  • Identifies critical research gaps to refine future clinical guidelines for pediatric pneumonia.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.